Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Knight Therapeutics Inc
T.GUD
Alternate Symbol(s):
KHTRF
Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select...
international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:GUD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(152)
•••
longrun86
X
View Profile
View Bullboard History
Comment by
longrun86
on Jan 21, 2024 6:44pm
RE:RE:RE:Jan 3rd Share Repurchase… 2,999,497
I have been checking SEDI and there is virtually nothing now. I am happy they went hard at the buybacks. My hope is that they make some big moves in 2024 in both capital deployment and operating
...more
(13)
•••
gudisgood
X
View Profile
View Bullboard History
Comment by
gudisgood
on Jan 07, 2024 6:49am
RE:Jan 3rd Share Repurchase… 2,999,497
We will still see growth from the current portfolio (plus the couple of launches) this year. Hopefully the Ambisome orders continue coming in as well. And for 2025, there are many launches scheduled
...more
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m
posted Nov 13, 2024 9:00am by
Freegold Ventures Limited
-
|
Four specific holes were drilled to facilitate additional metallurgical testing and were strategically designed to collect representative material from the deposit while improving infill drilling efforts. Approximately ~2,400 meters of ½ PQ core (~ 20 tonnes) have been shipped to BaseMet Labs in Kamloops, BC, where a comprehensive suite of metallurgical testing is currently underway ...read more
(152)
•••
longrun86
X
View Profile
View Bullboard History
Post by
longrun86
on Jan 06, 2024 2:07pm
Jan 3rd Share Repurchase… 2,999,497
Talk about putting their money where their mouth is with a $15.3m purchase! I am expecting big things from Knight this year from a business performance perspective. On a side note, I am very curious
...more
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Jan 04, 2024 1:00pm
Great to see another product LAUNCH TODAY!!
Imvexxy launched. More products to end users.
(1)
•••
Michel1234
X
View Profile
View Bullboard History
Post by
Michel1234
on Jan 04, 2024 10:10am
NCIB
Knight repurchase for cancellation on December 21: 2,999,497 shares at @5,10$. Just speculation but it could be the final portion of the shares owned by Medison? The extract below was in a press
...more
(1)
•••
Stockoman1
X
View Profile
View Bullboard History
Post by
Stockoman1
on Dec 22, 2023 9:18am
Interesting things going on....
https://www.theglobeandmail.com/investing/markets/stocks/GUD-T/pressreleases/22829458/
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Dec 19, 2023 11:00am
Qelbree - ADHD - huge opportunity
ADHD - more & more kids are affected by this & stand to benefit from a great therapeutic
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Dec 07, 2023 9:43am
Abbvie buying Cerevel for $8.7B
A huge premium (~73%) to stock price. showing lots of interest in industry following previous $10b purchase in oncology
(13)
•••
gudisgood
X
View Profile
View Bullboard History
Comment by
gudisgood
on Nov 30, 2023 10:33am
RE:Ardelyx, portalix biotherapeutics taking off today
The Ardelyx drug is now doing about a million per year in sales for us. The relative growth rate is nice but in absolute numbers it's still quite low. According to Ardelyx's latest 10-K, we
...more
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Nov 30, 2023 9:44am
Abbie to buy Immunogenicity for $10.1 Billion
On ovarian cancer drug. great for medical /pharma advances and shows how great value exists in the space. & opportunity... & need for global distribution partners
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Nov 29, 2023 2:04pm
Ardelyx, portalix biotherapeutics taking off today
Investments still held by Knight?
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Nov 09, 2023 8:27pm
A respectable quarter for sure!
Yes. A respectable quarter! We are seeing the team execute on multiple fronts . I think Samira even said how the current products are growing in lots of regions &
...more
(152)
•••
longrun86
X
View Profile
View Bullboard History
Comment by
longrun86
on Nov 09, 2023 2:42pm
RE:Update on Portfolio's Peak Potential
Finally a respectable quarter and some decent guidance! I have much higher expectations for Knight in 2024 than 2023. The platform must continue to grow and be profitable.
(13)
•••
gudisgood
X
View Profile
View Bullboard History
Post by
gudisgood
on Nov 09, 2023 9:28am
Update on Portfolio's Peak Potential
Potential yearly combined sales went from $50M-$75M to $70-$100M.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits
Explained: The Psychology of Options Trading with Practical Tips
Meet the Top 5 Best Online Brokerages in Canada
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023
Gold, growth and sustainability in focus for this resource company
Star Diamond Corporation Announces Third Quarter 2024 Results